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Abstract
Background: We have shown previously in mice, that infection with live viruses, including influenza/A and Semliki Forest
virus (SFV), induces systemic partial activation of lymphocytes, characterized by cell surface expression of CD69 and CD86,
but not CD25. This partial lymphocytes activation is mediated by type-I interferons (IFN-I). Importantly, we have shown that
c-irradiated SFV does not induce IFN-I and the associated lymphocyte activation.
Principal Findings: Here we report that, in contrast to SFV, c-irradiated influenza A virus elicits partial lymphocyte activation
in vivo. Furthermore, we show that when using influenza viruses inactivated by a variety of methods (UV, ionising radiation
and formalin treatment), as well as commercially available influenza vaccines, only c-irradiated influenza virus is able to
trigger IFN-I-dependent partial lymphocyte activation in the absence of the TLR7/MyD88 signalling pathways.
Conclusions: Our data suggest an important mechanism for the recognition of c-irradiated influenza vaccine by cytosolic
receptors, which correspond with the ability of c-irradiated influenza virus to induce cross-reactive and cross-protective
cytotoxic T cell responses.
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Introduction
We have reported previously, that live viral infections cause
IFN-I dependent, generalized and systemic partial activation of
lymphocytes, and this partial activation is characterized by
elevated expression of the early activation marker CD69 and the
co-stimulatory molecule CD86, but not the IL-2Ra chain, CD25
[1,2]. We have found that the vast majority of lymphocytes
undergo partial lymphocyte activation within 24h of infection with
any of a large number of viruses from different virus families, with
a return to base line levels at around day 5 post infection. In
addition, we have reported that the magnitude of the IFN-I
response and partial lymphocyte activation correlate with virus
dose and virulence, and that c-ray sterilized SFV failed to induce
this phenomenon [1,2].
It is well known that both Toll-Like Receptors (TLR) and
cytosolic receptors (RIG-1 and MDA-5) are involved in recogni-
tion of viral RNA genomes and subsequently trigger IFN-I
responses [3,4]. Thirteen TLR have been identified in mammals
and are expressed by macrophages, B cells, DC, T cells, fibroblasts
and epithelial cells [5,6]. The diversity of TLRs enables immune
cells expressing them to survey the host environment for the
presence of pathogens and each TLR binds a particular PAMP
[3]. While interactions of some cell surface expressed TLRs with
viral glycoproteins have been reported to signal the presence of
cytomegalovirus [7] or respiratory syncytial virus [8], recognition
of viral genomes by TLR3, 7, 8, and 9 within the endosomal
compartment facilitates the detection of most viral infections [9]. It
is currently accepted that dsRNA is recognised by TLR3, ssRNA
is recognised by TLR7 and 8, and unmethylated 2’-deoxyribo
(Cytidine-phosphate-guanosine) (CpG) DNA motifs present in
bacterial and viral DNAs are recognised by TLR9 [9]. Upon
recognition, homophilic Toll-Interleukin-I receptor (TIR) domains
of the adaptor proteins (MyD88 or TRIF) interact to activate a
cascade of proteins that result in IFN-I secretion [5]. Importantly,
endosomal acidification and influenza ssRNA is required to induce
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TLR7/MyD88 dependent pathways in pDC [10,11]. In addition
to viral recognition by TLRs, two cytosolic viral RNA receptors
have been identified, the caspase activation and recruitment
domain (CARD)-containing RNA helicases retinoic acid inducible
gene-1 (RIG-1) and melanoma differentiation antigen 5 (MDA-5)
[4]. RIG-I and MDA-5 bind cytoplasmic uncapped 5’-triphos-
phate RNA and cytoplasmic dsRNA, respectively, and activate
IFN-I gene expression via the IFN-b Promoter Stimulator 1 (IPS-
1) adaptor protein [3,4,12,13,14]. It has been reported that
plasmacytoid DC cells (pDCs) produce IFN-I in a TLR/MyD88
dependent and RIG-1 independent manner whereas myeloid DC
cells (mDCs) are dependent on cytosolic receptors for viral
recognition [15,16].
In this study, we used inactivated influenza virus to investigate
whether viral replication is an absolute requirement for partial
lymphocyte activation to occur. We demonstrate that, unlike
Semliki Forest virus (SFV), fully inactivated influenza virus is
capable of inducing partial lymphocyte activation in vivo, regardless
of the method used for inactivation. Furthermore, we used various
gene knockout mice to illustrate that c-irradiated influenza A virus
(c-flu), in contrast to other inactivated preparations, can induce
lymphocyte activation in the absence of TLR7 pathways, which
indicates recognition of inactivated virus by virus-specific cytosolic
receptors.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Australian National University and
The University of Adelaide. The protocol was approved by the
Animal Ethics Committee of the Australian National University
(Permit Number: JIG53.06) and the by the Animal Ethics
Committee of The University of Adelaide (Permit Number: S-
2010/099).
Viruses and cells
Madin-Darby canine kidney (MDCK), baby hamster kidney
(BHK), and T cell lymphomas (EL4, RMA, and transporter
associated with antigen processing (TAP)-deficient (RMA-S)) cell
lines were obtained from the American tissue culture collection
(ATCC). Cells were grown and maintained in EMEM plus 5%
FCS at 37uC in a humidified atmosphere with 5% CO2.
The influenza type A virus, A/PR/8 [A/Puerto Rico/8/34
(H1N1)] and A/PC [A/Port Chalmers/1/73 (H3N2)] was grown
in 10-day-old embryonated chicken eggs (HiChick, South
Australia). Each egg was injected with 0.1 ml normal saline
containing 1 hemagglutination unit (HAU) of virus, incubated for
48 h at 37 oC, and held at 4 uC overnight. The amniotic/allantoic
fluids were then harvested, pooled and stored at 280 oC. Viruses
were purified using chicken red blood cells as previously described
[17]. Briefly, infectious allantoic fluid is incubated with red blood
cells for 45 mins at 4 uC allowing the viral-hemagglutinin to bind
red blood cells, and then centrifuged to remove the allantoic fluid
supernatant. The pellets were resuspended in normal saline,
incubated for 1 h at 37 uC to release the virus from the red blood
cells and then centrifuged to remove the red blood cells and collect
the virus containing supernatant. Virus titres for A/PR8 and A/
PC were determined by standard plaque assay on MDCK cells.
Briefly, serial dilutions of virus stocks were assayed on MDCK cells
monolayers in 6-well tissue culture plates. After 1 h adsorption,
monolayers were overlaid with Eagle’s minimum essential medium
with Earle’s salts medium (EMEM) containing 1.8% Bacto-Agar
and incubated for 2–3 days. Cell monolayers were stained with
2.5% crystal violet solution and the plaques enumerated. Titres of
purified stocks were 56108 PFU/ml (or 76108 TCID50/ml) for
A/PC and 96108 PFU/ml (or 8.66108 TCID50/ml) for A/PR8.
The avirulent alphavirus, SFV was grown by infecting semi-
confluent Baby Hamster Kidney (BHK) cell monolayers at a
multiplicity of infection of 0.5 PFU per cell. Infected cells were
incubated for 24 h, culture supernatants were harvested and
centrifuged at 12006g for 4 min and stored in single-use aliquots
at 280 oC. Viral titres were determined by plaque assay on Vero
cells to be 107 PFU/ml.
Virus inactivation
For formalin inactivation, the viruses were incubated with 0.2%
formalin at 4 uC for a week [18]. The formalin was then removed
by pressure dialysis using normal saline for 24 h at 4 oC. The
dialysis method was adapted from Current Protocols in Immu-
nology [19]. For UV inactivation, viruses were placed in 60-mm
petri dishes with a fluid depth of 10 mm. The virus was exposed to
4000 ergs per cm2 for 45 mins at 4 oC. For gamma ray
inactivation, influenza viruses and aSFV received a dose of 10 kGy
and 40 kGy respectively from a 60Co source (Australian Nuclear
Science and Technology Organization – ANSTO). The virus
stocks were kept frozen on dry ice during gamma irradiation.
Sterility was tested by two independent methods: plaque assay
using MDCK cells; and by inoculating embryonated eggs. The
detection limit of our plaque assay is 10 PFU/ml and no plaque-
forming unit was detected for the irradiated samples. These tests
confirmed sterility in inactivated stocks. In addition, we have
estimated the minimum inoculum required to cause a positive
infection in embryonated eggs and found that the minimum egg-
infectious dose that causes detectable HA titers in the allantoic
fluid after 2 days of incubation is 0.1 PFU/egg. Embryonated eggs
were inoculated with 100 ml of inactivated preparations per egg
and incubated for 2 days at 37 uC and the allantoic fluid of
individual eggs was harvested and tested for virus replication using
HA assays. HA titers were negative in the allantoic fluid of these
eggs, which illustrates a complete loss of virus infectivity in our
inactivated preparations. The HAU titres of inactivated virus
stocks were determined to be 7.296104 HAU/ml for c-A/PR8,
2.436104 HAU/ml for formalin-A/PR8 and 8.16103 HAU/ml
for UV-A/PR8.
CSL fluvax split vaccine 2008 is egg derived, b-propiolactone
inactivated and contains 90 mg/ml of the hemagglutinin antigens
of influenza A/Solomon Islands/3/2006 H1N1, A/Brisbane/10/
2007 H3N2 and B/Florida/4/2006 (CSL Limited, Australia).
Solvay influvac subunit vaccine 2009 is egg derived, formalde-
hyde inactivated and contains 90 mg/ml of the hemagglutinin
antigens of influenza A/Brisbane/59/2007 H1N1, A/Brisbane/
10/2007 H3N2 and B/Brisbane/60/2008 (Solvay Biologicals
LLC, Spain)
For in vivo studies, mice were injected intravenously (i.v) in the
tail vein with 200 ml PBS containing either live or inactivated virus
(26107 PFU equivalent) or 200 ml (18 mg HA) of the trivalent
inactivated influenza vaccine (CSL fluvax or Solvay influvac).
Hemagglutination assay
Live, inactivated virus and trivalent influenza vaccine prepara-
tions were serially diluted in a 100 ml volume on 96-well U-bottom
microtiter plates. 0.5% chicken red blood cell suspensions were
added to all wells and plates were incubated for 30 min on ice.
This method was adapted from Current Protocols in Microbiology
[20].
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Mice
C57BL/6, 129Sv/Ev (WTGR), MHC-II knockout (H2AB2/2)
[21], interferon-type Ia receptor knockout (IFN-IR2/2) [22],
interferon-c receptor knockout (IFN-IIR2/2) [23], interferon type
I and II double receptors knockout (IFN-I&IIR2/2), myeloid
differentiation primary response gene 88 knockout (MyD882/2)
[24], Toll like receptor 3 (TLR32/2) [25], Toll like receptor 7
(TLR72/2) [26] mice were bred under specific pathogen-free
conditions and supplied by the Animal Services Division at the
John Curtin School of Medical Research, Canberra or the animal
services at the University of Adelaide, Adelaide. 10,14-week-old
females were used in these experiments. Mice deficient in
MyD882/2, TLR32/2, and TLR72/2 were used with permission
of Prof. S. Akira.
ELISA assays for serum IFN-a, -b levels
Serum samples were collected from influenza or SFV
immunized C57BL/6 mice at various time points post-immuni-
zation. IFN-a and -b levels in these serum samples were
determined by ELISA. Briefly, Nunc-Immuno 96 Microwell
plates were coated with monoclonal rat anti-mouse IFN-a (HyCult
Biotechnology). Plates were then sequentially incubated with
serum samples or a recombinant mouse IFN-a standard (HyCult
Biotechnology) for 2 h at room temperature followed by a
polyclonal rabbit anti-mouse IFN-a (PBL InterferonSource) for
2 h at rt and followed by horseradish peroxidase conjugated goat
anti rabbit IgG (Sigma) for 2 h at rt and followed by peroxidase
substrate (TMB substrate reagent set, Biosciences) for 30 mins.
Optical density was measured at 450 nm. Serum IFN-a
concentrations were estimated using a standard curve and
expressed as Units/ml. One unit of mouse interferon alpha/beta
is the amount of interferon alpha/beta which protects 50% of the
indicator CHO cell population from viral induced cell death.
For IFN-b ELISA, monoclonal rat anti-mouse IFN-b was used
(PBL InterferonSource) as capturing antibody and polyclonal
rabbit anti-mouse IFN-b (PBL InterferonSource) as the detecting
antibody. A recombinant mouse IFN-b (PBL InterferonSource)
was used for establishment of a standard curve.
Flow cytometric analysis
Spleens were harvested 1, 2 or 3 days post immunization and
red blood cell depleted splenocytes were washed in PBS with 2%
FCS. Fc receptors were blocked by incubation with mouse CD16/
CD32 (Fcc III/II receptor) Ab (BD Pharmingen) for 20 min at 4
oC. Cells were washed and further incubated with a mixture of
fluorescent-conjugated anti-CD3 (BD Pharmingen), anti-CD8 (BD
Pharmingen), anti-CD19 (BD Pharmingen), anti-CD11c (BD
Pharmingen), anti-CD25 (BD Pharmingen), anti-CD40 (abcam),
anti-CD69 (BD Pharmingen), anti-CD80 (abcam) or anti-CD86
(BD Pharmingen) Abs. Dead cells were labelled with 7-
aminoactinomycin D (Sigma-Aldrich). Stained cells were quanti-
tated using a FACSCalibur (Becton Dickinson).
51Cr release assay
C57BL/6J mice were injected i.v with c-irradiated A/PC. 7
days post-injection, spleens were harvested and red blood cell-
depleted splenocytes were used as effector cells. Target cells were
prepared by incubating EL4, RMA, and RMA-S T cell
lymphomas with live or inactivated (c-irradiated, formalin-
inactivated, UV-inactivated) A/PC, followed by 1 h of incubation
in medium containing 100 to 200 mCi of 51Cr. After three times
washing, target cells were mixed with effector cells at different
ratios and incubated for 8-h in a chromium release assay. The
level of radioactivity in the supernatant was measured in a gamma
counter. Specific lysis is given as mean percent lysis for triplicate
wells, and values were calculated using the formula [(experimental
cpm - spontaneous cpm)/(maximal release cpm - spontaneous
cpm)]6100.
Results
1. Live and gamma-irradiated influenza viruses induce
partial lymphocyte activation
We have previously reported that for the alphavirus SFV, viral
replication and subsequent IFN-I production is essential for the
induction of partial activation of lymphocytes [2]. To test whether
viral replication is a general requirement for systemic lymphocyte
activation, we inactivated influenza A virus using c-irradiation and
compared the immune stimulatory ability in vivo with that of live
and c-irradiated SFV. Mice were injected i.v with SFV, A/PR8 or
A/PC, or their c-irradiated counterparts, and the cell surface
expression of CD69, CD86, and CD25 was analyzed at days 1, 2
and 3 post-injections. Consistent with our previous report [2], c-
SFV failed to induce partial lymphocyte activation while both live
influenza (A/PR8 and A/PC) and their c-irradiated counterparts
induced up-regulation of CD69 expression on CD3+ T cells
(Figure 1). Expression profile of CD69 on CD19+ cells as well as
CD86 on both CD3+ and CD19+ cells were similar to that of
CD69 on CD3+ cells (data not shown). Consistent with our
previously published work [2], the level of partial lymphocyte
activation induced by live A/PR8 was dose dependent (Figure 2).
Similarly, we found the overall levels of partial lymphocyte
activation induced by live and inactivated preparations to be
transient as the cell surface expression of the activation markers
return to background levels by day 3 post-infection (Figure S1).
2. The ability of gamma-irradiated influenza virus to
induce IFN-I response
We addressed the question as to why c-A/PR8, but not c-SFV,
retained its ability to stimulate partial lymphocyte activation after
inactivation. We showed previously that systemic partial lympho-
cyte activation during acute viral infection requires IFN-I [1,2].
Thus, we investigated lymphocyte activation in type I and/or type
II IFN receptor(s) (IFN-IR2/2, IFN-IIR2/2, and IFN-I&IIR2/2)
deficient mice following i.v administration of A/PR8 or c-A/PR8.
As shown in Figure 3, elevated expression of CD69 was only
observed in wild-type 129 and IFN-IIR2/2 mice, but not in IFN-
IR2/2 or IFN-I&IIR2/2 mice. These data confirm our previously
published work regarding the role of IFN-I in lymphocyte
activation. Consequently, we compared serum levels of IFN-a
and IFN-b following i.v administration of live or c-irradiated A/
PR8 or SFV. As expected both live A/PR8 and SFV induced
elevated IFN-a levels in sera, reaching peak values at 6 and 12 h,
respectively, post infection and returned to background levels by
day 2 (Figure 4). Elevated IFN-a levels induced by c-A/PR8
peaked at 3 h post injection, and gradually declined to background
levels by day 2 (Figure 4A). In contrast, no elevation of serum IFN-
a was detected in mice injected with c-SFV (Figure 4C). The peak
IFN-a levels in mice treated with c-A/PP8 were substantially
higher than those seen with live A/PR8 suggesting a capacity of
live replicating virus to interfere with IFN-a responses. This is
concordant with the established IFN-I inhibitory role of the
influenza NS1 protein [27,28], which presumably would have to
be produced in substantial amounts for significant interaction. In
addition, our data show that live A/PR8 failed to increase IFN-b
serum levels at any time point post infection (Figure 4B). Thus,
differential induction of type I IFN-a and -b can be seen with both
Immune Responses to Inactivated Influenza Viruses
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live and inactivated influenza virus preparations. In contrast, SFV
induced IFN-b secretion with similar kinetics to that of IFN-a,
reaching the peak serum level at 6 h post infection (Figure 4D).
Importantly, c-SFV failed to induce either IFN-a or IFN-b.
Bacterial endotoxin has been reported previously as a possible
contaminant of egg grown viruses [29]. However, this is unlikely to
contribute to the observed ability of c-flu to induce IFN-I as we have
routinely tested for bacterial contamination in our virus preparations.
Nonetheless, in order to rule out this remote possibility, we tested cell
surface expression of CD69 and CD86 on splenocytes from TLR22/
2 and TLR42/2 mice following i.v injection of c-A/PR8. As shown
in Figure S2, both live and c-A/PR8 preparations induced IFN-I
mediated partial lymphocyte activation in TLR22/2 and TLR42/2
mice. Thus, the ability of c-flu to induce IFN-I response, compare to
c-SFV, is not related to bacterial contamination.
3. The role of influenza viral glycoproteins
Influenza virus is known as a lymphocyte mitogen [30]. The
binding of the viral hemagglutinin to MHC-II molecules is
believed to be responsible for influenza virus mitogenicity
[31,32,33]. To investigate this possibility, mice defective in both
a and b chains of MHC-II molecules (MHC-II2/2) were injected
i.v with live, c-irradiated or formalin-inactivated A/PR8. Spleno-
cytes were harvested 24 h later, and cell surface expressions of
CD86 and CD69 were analysed by FACS. An absence of MHC-II
molecules did not influence the ability of inactivated viruses to
induce CD69 (Figure 5) and CD86 (data not shown) expression on
CD3+ or CD19+ cells.
It has been reported previously that purified HA and NA
(subunit vaccine) do not induce IFN-I response [34]. Therefore, to
address a possible role of surface glycoproteins (HA and NA) in the
Figure 1. Gamma-irradiation renders SFV but not A/PR8 unable to induce partial lymphocyte activation. Mice were immunized i.v with
SFV, A/PR8, or A/PC and their c-irradiated counterparts. Splenocytes were harvested 24 h post immunization and cells were stained and analysed by
FACS. Dot plots show CD69 expression levels on CD3+ splenocytes.
doi:10.1371/journal.pone.0025765.g001
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observed in vivo lymphocyte activation, we immunized mice i.v
with either of two different formulations of commercially available
influenza vaccines: subvirion vaccine containing all the viral
components (CSL fluvax vaccine; A/Solomon Islands/3/2006
H1N1, A/Brisbane/10/2007 H3N2, B/Florida/4/2006; 18 mg
hemagglutinin) or subunit vaccine containing purified HA and NA
(A/Brisbane/59/2007 H1N1, A/Brisbane/10/2007 H3N2 and
B/Brisbane/60/2008; 18 mg hemagglutinin). Splenocytes were
harvested 24 h post immunization and analysed for expression of
activation markers. The magnitude of CD69 up-regulation
induced by immunization with the subvirion vaccine was similar
to that induced by live A/PR8 (Figure 6A). In contrast, the subunit
vaccine did not induce up-regulation of either CD69 expression on
CD3+ cells. The profile expression of CD86 was similar to that of
CD69 (data not shown). To confirm the involvement of IFN-I in
the induction of partial lymphocyte activation by the subvirion
vaccine, IFN-IR2/2 and wild-type mice were injected i.v with the
subvirion vaccine and their splenocytes were analyzed 24 h later.
The subvirion vaccine elicited up-regulation of cell surface
markers in wild-type129 but not in IFN-IR2/2 mice (Figure 6B).
This provides evidence that the in vivo up-regulation of CD69
induced by trivalent influenza vaccine is mediated by IFN-I. In
contrast, the subunit vaccine consisting of HA and NA viral
antigens lacked this ability. Consequently, the mitogenic activity of
surface glycoproteins has no or only a very limited role in the
observed in vivo lymphocyte activation.
4. The role of TLRs in the induction of lymphocyte
activation
Gamma-irradiated viruses are expected to be able to fuse with the
cell membrane, then releasing their contents into the cytoplasm in a
similar manner to their ‘live’ counterparts. Since c-ray inactivated
viruses are incapable of replication, they can only be recognised by
TLR7 and cytosolic receptors, consequently inducing IFN-I in
MyD88-dependent or IPS-I-dependent pathways, respectively. In
contrast, split (subvirion) vaccines consist of disrupted virus particles
Figure 2. Generalized partial lymphocyte activation during A/PR8 infection is dose dependent. Splenocytes from wild-type mice were
analysed for CD69 expression on CD3+ cells 24h following i.v injection of variable doses of A/PR8. Dot plots show fluorescence profiles of A/PR8
infected compared to naı¨ve mice.
doi:10.1371/journal.pone.0025765.g002
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and therefore viral RNAs are present in these preparations and can
only be recognised by TLR7 to induce IFN-I. In addition, formalin-
inactivated viruses are prone to have rigid virion structure due to
protein cross-linking [35,36]. Similar to subvirion vaccine, formalin-
inactivated influenza viruses are not expected to enter the host-cell
cytosol and consequently their viral RNAs can only induce IFN-I
Figure 3. Generalized partial lymphocyte activation is dependent on an IFN-I response. Splenocytes from IFN-IR2/2, IFN-IIR2/2, IFN-
I&IIR2/2 and wild-type 129 mice were analysed for CD69 expression on CD3+ cells 24h following in vivo immunization. Dot plots shows fluorescence
profiles from mock, live A/PR8 infected and c-A/PR8 immunized mice.
doi:10.1371/journal.pone.0025765.g003
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via TLR7-dependent pathway. To test these predictions, we
injected TLR32/2, TLR72/2, MyD882/2 and wild-type B6 mice
with the various inactivated influenza viruses and vaccine
preparations and tested lymphocyte activation 24h later. As shown
in Figure 7, splenocytes from all mouse strains (wild-type and
knockouts) expressed high levels of CD69 on CD19+ cells following
infection with live influenza virus. Similar data were observed for
CD69 expression on CD3+ cells and also for CD86 expression on
CD19+ and CD3+ cells (data not shown). Importantly, similar to live
virus, splenocytes from all mouse strains showed high levels of CD69
expression following i.v injection of c-A/PR8 (Figure 7B). In
contrast, i.v administration of formalin-A/PR8 or split TIV vaccine
(CSL vaccine) failed to induce lymphocyte activation in TLR72/2
and MyD882/2 mice (Figure 7C and D). Both preparations were,
however, capable of inducing lymphocyte activation in wild-type
and TLR32/2 mice. Considering that formalin-inactivation
affected the HAU quantity (3 fold reduction in HAU titres), we
treated TLR72/2, MyD882/2 and wild-type B6 mice with either
diluted c-flu (1:3 dilution) or undiluted formalin-inactivated vaccine
preparations and tested lymphocyte activation 24h later. As shown
in Figure 8, injection of live A/PR8 and diluted c-A/PR8, in
contrast to undiluted formalin-A/PR8, induced high levels of CD69
expression on CD19+ cells in wild-type and knockout mice. Similar
data were observed for CD69 expression on CD3+ cells and also for
CD86 expression on CD19+ and CD3+ cells (data not shown).
Therefore, the inability of formalin-inactivated flu to induce IFN-I-
dependent lymphocyte activation in TLR72/2 and MyD882/2
mice is not related to a reduced HA activity. Consequently, our data
regarding the ability of c-A/PR8 to induce IFN-I dependent
lymphocyte activation in TLR72/2 and MyD882/2 mice must be
related to the ability of c-A/PR8 to deliver inactivated viral
genomes and the associated viral proteins into the cytosol to be
recognised by cytosolic receptors.
5. Sensitisation of target cells for lysis by Tc cells
We have previously illustrated the ability of c-flu to induce
cross-reactive and cross-protective Tc cell responses [37,38,39,40].
It is well known that Tc cell responses are strictly regulated by
TCR-mediated recognition of viral antigens presented in the
context of MHC-I molecules. Therefore, in contrast to formalin-
inactivated preparation, c-flu must have the ability to deliver viral
Ag into MHC-I presentation pathway. To test this, we investigated
the ability of various inactivated influenza preparations to sensitise
mouse-derived EL4, RMA, and RMA-S T cell lymphomas for
lysis by Tc cells in vitro. Cells were incubated with a multiplicity of
infection of 1 PFU/cell for live A/PC and 10 PFU-equivalent/cell
of inactivated A/PC for 1 h. These treated cells were used as
targets in 51Cr release assays to test the cytolytic activity of primary
c-A/PC immune Tc cells in vitro (Figure 9). Our data clearly show
that both EL4 and RMA cell lines were sensitised by live A/PC
and c-A/PC to give significant lysis above mock treated control
targets (P,0.05, student’s T test). In contrast, formalin- or
Figure 4. Comparison of IFN-a (A&C) and IFN-b(B&D) serum levels in mice immunized i.v with either live and or inactivated viruses.
Mice were infected with SFV or A/PR8 or immunized with inactivated viruses (dose equivalent to 26107 PFU). Serum samples were tested for IFN-a
and IFN-b concentrations and data expressed as mean (SD) Units/ml.
doi:10.1371/journal.pone.0025765.g004
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UV-inactivated A/PC failed to sensitise both cell lines for Tc cell
lysis. Importantly, the TAP-deficient T lymphoma RMA-S cells,
which are deficient in MHC-I Ag presentation, are not sensitised
by c-flu compared to their wild-type RMA counterpart.
Therefore, c-flu, in contrast to UV or formalin inactivated
influenza virus can deliver Ag into MHC-I presentation pathway.
Discussion
We originally reported that infection of mice with live viruses
from a range of virus families (pox-, flavi-, alpha- orthomyxo- and
adenoviridae) results in rapid, systemic, but partial, lymphocyte
activation, that is mediated by IFN-I [1,2]. We had also previously
shown that SFV, when inactivated by ionising radiation, lost the
ability to induce IFN-I and consequently was unable to induce
partial lymphocyte activation. Here we initially analysed the ability
of inactivated influenza virus preparations to stimulate IFN-I-
mediated partial lymphocyte activation in vivo. The difference
between SFV and influenza virus in their ability to induce partial
lymphocyte activation after c-irradiation was surprising and raised
questions about our earlier conclusions [2], that viral replication
was necessary for the induction of this phenomenon.
We have reported previously that virus inactivation by c-
irradiation follows basic physical laws, including the concept of an
‘exponential low’, which means that there always exists a finite
probability that an organism may survive, irrespective of the
irradiation dose used [41]. This proviso, however, does not affect
the outcome of our study as irradiated preparations were subjected
to infectivity testing. The sterility of irradiated preparations was
tested by plaque assay on MDCK cells (for influenza) and Vero
cells (for SFV). The detection limit of our plaque assay is 10 PFU/
ml and no plaques were detected for any irradiated sample used in
our studies. Furthermore, we tested the sterility of irradiated
influenza preparation in 10-day embryonated eggs and found no
detectable HA titers in the allantoic fluid of the inoculated eggs.
Furthermore, our present (Figure 2) and published [2] data clearly
show that the level of lymphocyte activation 24 h post infection is
dose dependent and requires infectious doses far in excess of our
Figure 5. Generalized partial lymphocyte activation in MHC-II2/2
mice. Splenocytes from MHC-II2/2 mice were analysed for CD69
expression on CD3+ and CD19+ cells 24h after i.v injection of live or
inactivated A/PR8.
doi:10.1371/journal.pone.0025765.g005
Figure 6. Subvirion, but not subunit, vaccine induces IFN-I
dependent lymphocyte activation. A) Wild-type B6 mice were
immunized i.v with either live (26107 PFU) or subvirion vaccine (CSL
fluvax vaccine; A/Solomon Islands/3/2006 H1N1, A/Brisbane/10/2007
H3N2, B/Florida/4/2006; 18 mg hemagglutinin) or subunit vaccine
containing purified HA and NA (A/Brisbane/59/2007 H1N1, A/Brisbane/
10/2007 H3N2 and B/Brisbane/60/2008; 18 mg hemagglutinin). B) wild-
type 129 and IFN-IR2/2 mice were immunized with subvirion vaccine.
Splenocytes were harvested 24h post immunization and analysed for
CD69 expression on CD3+ cells.
doi:10.1371/journal.pone.0025765.g006
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detection limit of 10 PFU/ml (or 2 PFU/mouse). Therefore, any
residual virus infectivity can be ruled out to contribute to the
observed partial lymphocyte activation.
Gamma-irradiation is known to generate nicks in the nucleic
acid genome without affecting virion structure [41]. Consequently,
c-irradiated viruses are capable of fusion with cell membranes and
release their contents into the cytoplasm. Our data clearly show
that i.v administration of c-flu, but not c-SFV, induces both
lymphocyte activation and IFN-I responses. It is important to
consider that 1) both influenza and SFV are enveloped ssRNA
viruses, 2) c-ray inactivated viruses are unable to replicate and 3)
systemic partial lymphocyte activation is IFN-I dependent [1,2].
Therefore, the difference in the ability of irradiated viruses to
induce lymphocyte activation may be related to their ability to
directly interact with cDCs and/or pDCs. However, Hidmark AS
and colleagues have reported that recombinant SFV can induce
systemic IFN-I synthesis in wild-type and MyD882/2 mice [42].
They have also shown that IFN-I production by mDCs cultures to
be independent of viral replication, but dependent on IRF3. On
the other hand, influenza A virus has been shown to infect DCs
[43,44]. Thus, both viruses appear to have the ability to interact
directly with DCs. Furthermore, recent studies have proposed a
genome-independent pathway of IFN-I induction, in which
influenza glycoproteins are recognized as the primary stimuli
triggering IFN-I production. For example, Miller and Anders [45]
showed that influenza virus-infected fixed cells were able to induce
IFN-I production in vitro. The authors argued that fixed influenza
virus-infected cells may present arrays of viral glycoproteins on
their cell surface that may interact with an as yet unidentified
receptor on IFN-I producing cells. However, this possibility is
ruled out by the inability of the purified surface glycoproteins
(commercially available subunit vaccine) to induce IFN-I depen-
dent lymphocyte activation. In addition, the crucial role of TLR7
in the induction of lymphocyte activation by subvirion and
Figure 7. Gamma-irradiated influenza vaccine induces lymphocyte activation in the absence of TLR7/MyD88 signalling pathway.
Splenocytes from wild-type 129, TLR32/2, TLR72/2 and MyD882/2 mice were analysed for CD69 expression on CD19+ cells 24h following i.v injection
of live A/PR8, gamma-irradiated-A/PR8, formalin inactivated A/PR8 and subvirion vaccine.
doi:10.1371/journal.pone.0025765.g007
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formalin-inactivated vaccine illustrates the need for viral genome
recognition. Therefore, it is not obvious at present why c-SFV, but
not c-Flu, fails to elicit IFN-I and lymphocyte activation in mice
and further work is clearly needed to solve this discrepancy.
Nonetheless, we focused on the recognition of inactivated
influenza vaccines and the associated induction of IFN-I and
lymphocyte activation. It is currently accepted that TLR7 and
TLR3 mediate the endosomal recognition of viral ssRNA and
dsRNA genomes and that they are preferentially expressed by
pDCs and mDCs, respectively [46,47]. In addition, 5’-triphos-
phate RNA can be recognised by RIG-I cytoplasmic receptors.
Interestingly, a recent study investigating the immunogenicity of
various inactivated influenza vaccines has reported that whole b-
propiolactone inactivated H5N1 preparations, but not subunit
vaccines, trigger IFN-I responses via TLR7 recognition of viral
ssRNA [34]. We confirmed the role of TLR7 in the recognition of
whole inactivated influenza vaccines. However, our data regarding
the commercially obtained split vaccine clearly contradicts
published findings related to lab-made split vaccines. Nonetheless,
both studies illustrated the ability of inactivated influenza vaccines
to induce IFN-I responses. Importantly, our data illustrate the
ability of c-irradiated influenza virus to induce partial lymphocyte
activation in TLR72/2 and MyD882/2 mice, which indicates the
possible recognition of the inactivated (nicked) viral genomes by
cytosolic receptors. This must be associated with the delivery of
structural internal viral proteins, including the nucleoprotein,
source of the dominant peptide determinants, into the cytosol of
APCs with a consequent Ag presentation via MHC-I and
subsequent T cell priming. To confirm this possibility, we tested
the ability of c-flu to sensitise mouse-derived EL4, RMA, and
RMA-S cells for lysis by influenza-immune Tc cells. Our data
clearly illustrate the ability of c-flu, in contrast to other inactivated
preparations, to sensitise both EL4 and RMA, but not RMA-S,
cells. It is important to note that RMA-S cells were originally
selected from mutagenized RMA cells on the basis of low cell
surface expression of class I molecules [48], and that RMA-S cells
have been reported previously to be unable to present influenza
virus nucleoprotein to H-2Db-restricted (C57BL/6J) Tc cells [49].
Therefore, our data regarding the ability of c-flu to induce IFN-I
dependent lymphocyte activation in TLR72/2 and MyD882/2
mice as well as the ability to sensitise RMA cells to lysis by
influenza-immune Tc provides conclusive evidence of the ability of
c-flu to deliver internal viral proteins into the cytosol of APCs. In
conclusion, data presented in this study provide an explanation as
to why c-ray inactivated, but not UV or formalin inactivated,
influenza viruses induce cross-reactive Tc cell responses [39] with
the potential to lead to the development of a cross-protective
‘‘universal’’ influenza vaccine [40,50].
Figure 8. Gamma-irradiated influenza vaccine induces lym-
phocyte activation in the absence of TLR7/MyD88 signalling
pathway. Splenocytes from wild-type 129, TLR72/2 and MyD882/2
mice were analysed for CD69 expression on CD19+cells 24h following i.v
injection of live A/PR8, 1:3 diluted gamma-irradiated-A/PR8, or un-
diluted formalin inactivated A/PR8.
doi:10.1371/journal.pone.0025765.g008
Figure 9. Target cell sensitization. EL4 (A), RMA (B) or RMA-S (C) cells were incubated with a multiplicity of infection of 1 PFU of live or 10 PFU-
equivalent of inactivated (gamma-, formalin- or UV-) A/PC. These cells were used as targets in 51Cr release assay. Effectors cells were generated by i.v
injection of C57BL/6 mice with gamma-inactivated A/PC (108 PFU equivalent) and splenocytes harvested 7 days post-injection. Each bar represents
the mean percentage 6 S.D. Specific lysis values were interpolated from a regression curve at effector:target ratio of 40:1.
doi:10.1371/journal.pone.0025765.g009
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Supporting Information
Figure S1 Kinetics of partial lymphocyte activation of
splenocytes from immunized mice. C57BL/6 mice were
injected i.v with either live (26107 PFU) or inactivated viruses
(26107 PFU equivalent); live A/PR8, gamma-inactivated A/PR8,
formalin-inactivated A/PR8 or UV-inactivated A/PR8 and mock
treated (dotted line). Splenocytes were harvested at 1, 2 and 3 days
post injection and analysed for cell surface expressions of CD69
and CD86 on CD3+ or CD19+ cells. Data presented as percentage
of cells expressing the surface marker. Data represent the mean 6
SD of two mice per group.
(TIF)
Figure S2 Gamma-irradiated influenza virus induces
lymphocyte activation in TLR42/2 and TLR22/2 mice.
Splenocytes from TLR42/2 (A) and TLR22/2 (B) were analysed
for CD69 and CD86 expression on CD3+ and CD19+ cells
following in vivo injection of c-A/PR8. Dot plots shows
fluorescence profiles of immunized mice and mock treated mice.
Day 1 post immunization data are shown.
(TIFF)
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